Bipolaris sorokiniana-Induced Black Point, Common Root Rot, and Spot Blotch Diseases of Wheat: A Review

AM Al-Sadi - Frontiers in cellular and infection microbiology, 2021 - frontiersin.org
Wheat is among the ten top and most widely grown crops in the world. Several diseases
cause losses in wheat production in different parts of the world. Bipolaris sorokiniana …

An update on pharmacotherapy for leishmaniasis

S Sundar, J Chakravarty - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Current and emerging medications for the treatment of leishmaniasis

J Chakravarty, S Sundar - Expert opinion on pharmacotherapy, 2019 - Taylor & Francis
Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

Amphotericin B: A drug of choice for Visceral Leishmaniasis

S Kumari, V Kumar, RK Tiwari, V Ravidas, K Pandey… - Acta Tropica, 2022 - Elsevier
Visceral leishmaniasis or Kala-azar is a vector-borne disease caused by an intracellular
parasite of the genus leishmania. In India, Amphotericin B (AmB) is a first-line medication for …

Chemotherapeutics of visceral leishmaniasis: present and future developments

S Sundar, A Singh - Parasitology, 2018 - cambridge.org
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …

Recent developments and future prospects in the treatment of visceral leishmaniasis

S Sundar, A Singh - Therapeutic advances in infectious …, 2016 - journals.sagepub.com
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …

Leishmaniasis: treatment updates and clinical practice guidelines review

NK Copeland, NE Aronson - Current Opinion in Infectious …, 2015 - journals.lww.com
Leishmaniasis remains a neglected tropical disease, with a need for additional clinical trials
with better design and reported endpoints to lead evidence-based treatment …

New insights into leishmaniasis in the immunosuppressed

H Akuffo, C Costa, J van Griensven… - PLoS neglected …, 2018 - journals.plos.org
Immunosuppression contributes significantly to the caseload of visceral leishmaniasis (VL).
HIV coinfection, solid organ transplantation, malnutrition, and helminth infections are the …

Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence

S Sundar, OP Singh, J Chakravarty - Expert review of anti-infective …, 2018 - Taylor & Francis
Introduction: Visceral leishmaniasis (VL) is a fatal parasitic disease caused by a parasite
belonging to the Leishmania donovani complex and transmitted by infected female …

Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context

R Molina, M Jimenez, J García-Martínez… - PLoS Neglected …, 2020 - journals.plos.org
Background In the Mediterranean basin, Leishmania infantum is the causative agent of
visceral leishmaniasis (VL), a zoonosis in which the dog is the primary domestic reservoir …